Pregabalin Capsule 25 mg (Pregabalin)
Pregabalin
Prescription medication
Cosmax Pharma Co., Ltd.
MFDS item code 201901230 · Approved 2019.02.26
This product's status changed to Approval withdrawn on 2023.07.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures, with or without secondary generalization, in epilepsy patients. Additionally, it is effective in treating fibromyalgia. It aids in alleviating major neurological pain, seizures, and musculoskeletal symptoms, thereby improving the quality of life for patients.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. After an additional week, it may be increased to the target dose of 600mg daily. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg–450mg daily. The initial dose is 75mg twice daily (150mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg daily). For patients who do not experience sufficient benefit at a dose of 300mg daily, the dose may be increased within 1 week to 225mg twice daily (450mg daily). Clinical studies have also been conducted with a dose of 600mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 (mL/min): Starting dose (mg/day) 150, maximum dose (mg/day) 600, BID or TID ≥30 -<60: Starting dose (mg/day) 75, maximum dose (mg/day) 300, BID or TID ≥15 -<30: Starting dose (mg/day) 25-50, maximum dose (mg/day) 150, QD or BID <15: Starting dose (mg/day) 25, maximum dose (mg/day) 75, QD Supplemental dose after hemodialysis: 25 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose means an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is needed in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, thus mood or behavior changes should be closely monitored during use. Patients with hypersensitivity to this medication or with genetically determined lactose intolerance should not take it. Diabetic patients should be aware that weight gain may affect blood sugar control. Immediate discontinuation of the medication is necessary if serious allergic reactions such as angioedema occur. Elderly patients should be cautious due to risks of dizziness or drowsiness, which may lead to injuries, and may experience vision changes such as blurred vision. Discontinuing this medication suddenly can result in withdrawal symptoms such as insomnia, headaches, or anxiety, and should be tapered off gradually under medical guidance. Due to the potential for drug abuse or dependence, patients must inform healthcare providers of their mental health status and history of drug use. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should take this medication with caution. Due to its central nervous system depressant effects, there may be increased risk of respiratory depression when used with opioids or other depressants. During early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant must consult their healthcare provider and use effective contraception. Breastfeeding women should discuss with their doctor whether to discontinue breastfeeding or the medication since it may be passed into breast milk. Risky activities such as driving or operating machinery should be avoided until the dizziness or drowsiness from the medication has resolved. In the event of severe skin reactions, the medication should be immediately discontinued, and healthcare providers should be notified. In case of overdose, immediate hospital care is required, and blood dialysis may be performed if needed. This medication should be stored out of reach of children, and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air and moisture ingress, preferably in a cool place between 15 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness over time.
A hard capsule with a pale yellow upper part and white lower part containing a white powder that is white or light yellow.
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin
Prescription medication
Cosmax Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.